179 related articles for article (PubMed ID: 22526864)
21. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
22. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
[TBL] [Abstract][Full Text] [Related]
23. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
24. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
[TBL] [Abstract][Full Text] [Related]
25. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
27. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
28. Comparison of respiratory parameters and plasma cytokine levels between treatment with Salmeterol/fluticasone and ipratropium/terbutaline/budesonide in mechanically ventilated COPD patients.
Wu HP; Liu YC; Lin SC; Chien MY; Liao FC; Chang SC; Shieh WB
Chang Gung Med J; 2012; 35(5):373-81. PubMed ID: 23127342
[TBL] [Abstract][Full Text] [Related]
29. Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of β2-Adrenergic Receptors.
Gimenez LE; Baameur F; Vayttaden SJ; Clark RB
Mol Pharmacol; 2015 Jun; 87(6):954-64. PubMed ID: 25784721
[TBL] [Abstract][Full Text] [Related]
30. Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.
Xia N; Wang H; Nie X
PLoS One; 2015; 10(9):e0137904. PubMed ID: 26378450
[TBL] [Abstract][Full Text] [Related]
31. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
[TBL] [Abstract][Full Text] [Related]
32. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
33. Beta2-adrenergic receptor polymorphisms as a determinant of preferential bronchodilator responses to β2-agonist and anticholinergic agents in Japanese patients with chronic obstructive pulmonary disease.
Konno S; Makita H; Hasegawa M; Nasuhara Y; Nagai K; Betsuyaku T; Hizawa N; Nishimura M
Pharmacogenet Genomics; 2011 Nov; 21(11):687-93. PubMed ID: 21881540
[TBL] [Abstract][Full Text] [Related]
34. Variants of the ADRB2 Gene in COPD: Systematic Review and Meta-Analyses of Disease Risk and Treatment Response.
Nielsen AO; Jensen CS; Arredouani MS; Dahl R; Dahl M
COPD; 2017 Aug; 14(4):451-460. PubMed ID: 28506092
[TBL] [Abstract][Full Text] [Related]
35. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
[TBL] [Abstract][Full Text] [Related]
36. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
37. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.
Bleecker ER; Yancey SW; Baitinger LA; Edwards LD; Klotsman M; Anderson WH; Dorinsky PM
J Allergy Clin Immunol; 2006 Oct; 118(4):809-16. PubMed ID: 17030231
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
[TBL] [Abstract][Full Text] [Related]
39. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
Cave AC; Hurst MM
Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
[TBL] [Abstract][Full Text] [Related]
40. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
Wang J; Nie B; Xiong W; Xu Y
J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]